- Strong global academic relationships with research groups
- Continuous development of the geneType portfolio
- A deep pipeline of new unique and ground-breaking tests
Strong Global Academic and Research Partnerships
GTG’s global academic connections are exemplified by the Company’s collaboration with several high-profile universities involving a range of translational research projects, all focused on delivering a platform for the next generation of risk assessments tests.
Some examples of these projects include but are not limited to:
- CASSOWARY project; a clinical trial in which GTG is collaborating with
University of Melbourne ,Queen Mary University of London ,The Royal Melbourne Hospital ,Royal Marsden NHS Foundation Trust , and the Daffodil Centre to develop the utility of risk prediction tools, such as geneType in general practice. This important study will include 8 General Practices and 600 patients. GTG is one of the co-co-principal investigators of this trial led by ProfessorJon Emery . - BRCA 1/2 modifier project in breast cancer risk. GTG is the laboratory service provider leveraging the company’s NY State and CLIA certifications. Two ongoing studies with investigators at Memorial
Sloane Kettering and theOhio State University are close to wrapping up. Discussions are ongoing with these and additional institutions to use GTG as the lab service provider for subsequent studies in the Polygenic Risk Score (PRS) modifier space across other cancers in addition to breast. - GTG has provided letters of support as the lab service provider for future opportunities subject to grant funding with investigators at
Fred Hutchinson Cancer Center (Seattle ), investigators from St. Vincent’s Hospital (Sydney ), and investigators from theCouncil of the Queensland Institute of Medical Research . - Utility of Breast PRS in mammography; a clinical study assessing the integration of geneType’s population risk assessment within breast imaging centres with
University of Melbourne and ProfessorsJohn Hopper andJon Emery . - A range of internally funded research projects with US breast centres in
New York ,Miami andHouston to pilot the integrated risk assessment within an imaging facility.
These research projects highlight GTG’s deep commitment to expand the risk assessment testing space enabling more effective stratification of patients at risk of developing serious disease.
Continuous Enhancement of Current Portfolio
GTG continues to drive enhancement and validation of the current geneType portfolio with a pipeline of publications in quality peer reviewed journals including:
- Nurses’ health study collaboration with Professor
Bernard Rosner fromHarvard School of Public Health ovarian cross validation. - Colorectal Cancer risk assessment model improvement within
UK Biobank . - An 800-subject case/control cross validation study of African genetic ancestry with
Washington University (St Louis ). - Implementation of genetic inferred ancestry into the geneType commercial test.
- Women’s Health Initiative (WHI) including a multi-ethnic cross validation of Breast Cancer, Colorectal Cancer and Ovarian Cancer models.
- Study to cross validate data from the geneType cardiology-focused risk assessment tests with a multi-ethnic cohort.
Advancing the geneType Pipeline
GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care. Leveraging this approach GTG is expanding the portfolio with the following new tests:
- Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS. There is interest in this type of test from the high-risk centres.
- Finalising the rollout of the comprehensive geneType (high penetrant gene panel for all 9 of the geneType diseases). This test would include an extensive gene panel added to the patented geneType multi-risk test.
- Developing a new geneType risk assessment tests that may include diseases like lung cancer. Oncology based risk assessment tests have strong interest from Big Pharm and government particularly when it can be incorporated into the rapidly expanding liquid biopsy space.
GTG’s CEO,
Approved for release by the Chair of Board of Directors.
Enquiries
Investor Relations
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au
About
Source:
2024 GlobeNewswire, Inc., source